Filings monitor · BSX

What BOSTON SCIENTIFIC CORP's SEC filings said

10-Q for 2026Q3, filed 2 Nov 2026. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

1. Income Tax Rate Changes71 · importance in its document · 10-Q · 2026Q3
   The reported tax rate for the first nine months of 2026 was 4.5%, compared with 17.2% in the same 2025 period; the rate from continuing operations was 17.4% versus 18.1%. A $383 million discrete tax benefit in the first quarter reflected…
2. Acquisition / Partnership / Divestiture71 · importance in its document · 10-Q · 2026Q3
   Boston Scientific agreed to acquire 100% of Penumbra for approximately $14.5 billion, valued at $374 per share when announced on January 15, 2026. Penumbra stockholders approved the transaction on May 6, 2026, and the companies were…
3. Restructuring and Cost Savings58 · importance in its document · 10-Q · 2026Q3
   On July 21, 2026, the Board approved and Boston Scientific committed to a new global restructuring program intended to improve cost efficiency and align resources with strategic priorities. The 2026 Restructuring Plan is expected to…
4. Stock Repurchase Program57 · importance in its document · 10-Q · 2026Q3
   On February 18, 2026, the board added $4.0 billion to the existing $1.0 billion share-repurchase authorization, bringing the total authorization to $5.0 billion. Under an accelerated share repurchase agreement, Boston Scientific paid…
5. Operating Income and Margins55 · importance in its document · 8-K exhibit · 28 Oct 2026
   Third-quarter operating income fell 21.0% to $828 million from $1.048 billion, while operating margin declined to approximately 16.1% from 20.7%. Total operating expenses rose to $2.600 billion from $2.494 billion, with $81 million of…

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 2 Nov 2026

Full report · Filing on EDGAR

• Income Tax Rate ChangesImportance 71
  The reported tax rate for the first nine months of 2026 was 4.5%, compared with 17.2% in the same 2025 period; the rate from continuing operations was 17.4% versus 18.1%. A $383 million discrete tax benefit in the…
• Acquisition / Partnership / DivestitureImportance 71
  Boston Scientific agreed to acquire 100% of Penumbra for approximately $14.5 billion, valued at $374 per share when announced on January 15, 2026. Penumbra stockholders approved the transaction on May 6, 2026, and the…
• Restructuring and Cost SavingsImportance 58
  On July 21, 2026, the Board approved and Boston Scientific committed to a new global restructuring program intended to improve cost efficiency and align resources with strategic priorities. The 2026 Restructuring Plan…
• Stock Repurchase ProgramImportance 57
  On February 18, 2026, the board added $4.0 billion to the existing $1.0 billion share-repurchase authorization, bringing the total authorization to $5.0 billion. Under an accelerated share repurchase agreement, Boston…
• Cybersecurity Incident DisruptionImportance 53
  Boston Scientific identified a cybersecurity incident in August 2026 that disrupted global operations, including manufacturing and the processing and shipment of customer orders. The company said the incident…
• Revenue Performance and MixImportance 43
  Net sales increased 1.5% to $5.138 billion in the third quarter of 2026 and 6.7% to $15.784 billion in the first nine months, with nine-month organic growth of 5.8%. Nine-month Cardiovascular sales grew 7.8% to $10.532…
• Net Income and EPS PerformanceImportance 38
  Third-quarter reported net income attributable to Boston Scientific common stockholders declined 22.9% year over year, and diluted EPS fell 20.6% to $0.40. Adjusted net income declined 5.5% to $1.063 billion and…
• Gross Margin DriversImportance 33
  Third-quarter gross profit was $3.428 billion, down from $3.542 billion a year earlier, and gross margin declined from 69.9% to 66.7%. The 3.2-percentage-point quarterly margin decline included a 1.7-point adverse…
• Competition and Market ShareImportance 26
  Boston Scientific reported increased competition in its Electrophysiology business unit during the third quarter and first nine months of 2026. Competition offset growth in Cardiovascular and contributed to pressure on…
• Products and TechnologyImportance 26
  Boston Scientific attributed Cardiovascular growth to its coronary therapies franchise, led by the AGENT Drug-Coated Balloon, and, for the first nine months, to Electrophysiology led by the Farapulse Pulsed Field…
• Operating Cash Flow and CapexImportance 25
  Operating cash flow was $2.870 billion in the first nine months of 2026, down $301 million from the prior-year period, primarily because of increased working-capital payments. Investing activities used $2.984 billion,…
• China Pricing PressureImportance 20
  Volume-based procurement (VBP) in China contributed to third-quarter Endoscopy sales declines. In Urology, VBP-related underperformance in the stone franchise contributed to declines in both the third quarter and first…

8-K filings last 12 months

• Results, no stated guidance change28 Oct 2026 · 8-K Item 2.02 · Routine · rule score 10
  Read from the attached exhibit: Operating Income and Margins · Income Tax Rate Changes · Guidance / Outlook
• Other officer change7 Oct 2026 · 8-K Item 5.02 · Routine · rule score 15
  “On October 7, 2026, Boston Scientific Corporation (the “Company”) announced that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief…”
  Read from the attached exhibit: Acquisition / Partnership / Divestiture · Leadership Transition · Strategic Operating Structure
• Other officer change23 Sept 2026 · 8-K Item 5.02 · Routine · rule score 15
  “On September 21, 2026, Arthur C. Butcher informed Boston Scientific Corporation (the “Company”) that he has decided to retire from his role as Executive Vice President and Group President, MedSurg and Asia Pacific effective as of January…”
• Results (release not read)29 Jul 2026 · 8-K Item 2.02 · Routine · rule score 20
  Read from the attached exhibit: Acquisition / Partnership / Divestiture · Stock Repurchase Program · Guidance / Outlook
• Restructuring, first in three years27 Jul 2026 · 8-K Item 2.05 · Flagged · rule score 65
• Press release attached to an 8-K18 May 2026 · 8-K
  Read from the attached exhibit: Capital Return Program · Guidance / Outlook
• Press release attached to an 8-K18 May 2026 · 8-K
  Read from the attached exhibit: Acquisition / Partnership / Divestiture · Product Pipeline Progress · Regulatory Approval Milestones
• Results (release not read)22 Apr 2026 · 8-K Item 2.02 · Routine · rule score 20
• New debt26 Feb 2026 · 8-K Items 1.01, 2.03 · Routine · rule score 35
  “On February 26, 2026, Boston Scientific Corporation (the “ Company ”) entered into a $3.000 billion revolving credit agreement (the “ 2026 Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party…”
• Board change23 Feb 2026 · 8-K Item 5.02 · Routine · rule score 10
  “On February 18, 2026 the Board of Directors (the “ Board ”) of Boston Scientific Corporation (the “ Company ”), upon the recommendation of the Nominating and Governance Committee of the Board, increased the number of directors comprising…”
• Other officer change5 Feb 2026 · 8-K Item 5.02 · Routine · rule score 15
  “On February 2, 2026, Yoshiaki Fujimori informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).”
• Results (release not read)4 Feb 2026 · 8-K Item 2.02 · Routine · rule score 20
• Agreement to acquire a business15 Jan 2026 · 8-K Item 1.01 · Routine · rule score 45
  “On January 14, 2026, Boston Scientific Corporation, a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Pinehurst Merger Sub, Inc., a Delaware corporation and wholly owned…”
• Executive pay change19 Nov 2025 · 8-K Item 5.02 · Routine · rule score 5
  “2026 Annual Bonus Plan On November 18, 2025, upon the recommendation of the Executive Compensation and Human Resources Committee (the “Compensation Committee”), the Board of Directors (the “Board”) of Boston Scientific Corporation (the…”

Earlier reports

• 10-Q · 2026Q2filed 3 Aug 2026
  Acquisition / Partnership / Divestiture · Regulatory Risk · Income Tax Rate Changes

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.